
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8424125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 2293-2300.	1.2	1,236
2	Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5593-5602.	1.8	1,184
3	Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2454-2462.	1.8	774
4	Prevalence and natural history of adrenal incidentalomas. European Journal of Endocrinology, 2003, 149, 273-285.	1.9	500
5	Cushing's syndrome. Lancet, The, 2001, 357, 783-791.	6.3	332
6	Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 115-122.	1.8	274
7	High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology, 2004, 61, 768-777.	1.2	239
8	Risk factors and long-term outcome in pituitary-dependent Cushing's disease Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2647-2652.	1.8	226
9	Approach to the Patient with Possible Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3121-3131.	1.8	219
10	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 520-526.	1.8	203
11	Placebo-controlled double-blind randomized trial on the use of l-carnitine, l-acetylcarnitine, or combined l-carnitine and l-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility, 2005, 84, 662-671.	0.5	195
12	Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clinical Endocrinology, 1991, 35, 347-352.	1.2	194
13	Expanding role of AMPK in endocrinology. Trends in Endocrinology and Metabolism, 2006, 17, 205-215.	3.1	190
14	Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility, 2009, 91, 1785-1792.	0.5	170
15	Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. Journal of Hypertension, 2007, 25, 177-186.	0.3	167
16	Quality of life of hirsute women. Postgraduate Medical Journal, 1993, 69, 186-189.	0.9	162
17	The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC–MS/MS method in routine clinical practice. European Journal of Endocrinology, 2014, 171, 1-7.	1.9	161
18	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 55-62.	1.8	160

#	Article	IF	CITATIONS
19	LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1375-1383.	1.8	160
20	Left ventricular structural and functional characteristics in Cushing's syndrome. Journal of the American College of Cardiology, 2003, 41, 2275-2279.	1.2	159
21	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591.	1.3	149
22	AMPâ€activated protein kinase mediates glucocorticoid―induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal, 2008, 22, 1672-1683.	0.2	148
23	Pathophysiology of Dyslipidemia in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 86-90.	1.2	147
24	Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3662-3666.	1.8	141
25	Development of overt Cushing's syndrome in patients with adrenal incidentaloma. European Journal of Endocrinology, 2002, 146, 61-66.	1.9	140
26	Clinical Correlates of Major Depression in Cushing's Disease. Psychopathology, 1998, 31, 302-306.	1.1	134
27	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. Journal of Hypertension, 2006, 24, 737-745.	0.3	133
28	Aldosterone as a cardiovascular risk factor. Trends in Endocrinology and Metabolism, 2005, 16, 104-107.	3.1	128
29	Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism, 2005, 16, 114-119.	3.1	125
30	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2573-2575.	1.8	121
31	Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3662-3666.	1.8	118
32	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	5.5	116
33	Coenzyme q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertility and Sterility, 2004, 81, 93-98.	0.5	115
34	Prolonged Treatment of Cushing's Disease by Ketoconazole. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 718-722.	1.8	114
35	Role of Nitric Oxide Concentrations on Human Sperm Motility. Journal of Andrology, 2004, 25, 245-249.	2.0	114
36	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114

MARCO BOSCARO

#	Article	IF	CITATIONS
37	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	1.8	113
38	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 301-308.	1.9	111
39	I. Adrenal Cortex and Steroid 21-Hydroxylase Autoantibodies in Adult Patients with Organ-Specific Autoimmune Diseases: Markers of Low Progression to Clinical Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 932-938.	1.8	109
40	Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing??s syndrome. Blood Coagulation and Fibrinolysis, 1999, 10, 145-152.	0.5	96
41	Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. European Journal of Endocrinology, 2004, 150, 339-344.	1.9	95
42	Adrenal incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 405-419.	2.2	94
43	Cardiovascular Risk In Cushing's Syndrome. Pituitary, 2004, 7, 253-256.	1.6	93
44	DIAGNOSIS AND MANAGEMENT OF ADRENAL INCIDENTALOMAS. Journal of Urology, 2000, 163, 398-407.	0.2	91
45	The fibrinolytic potential in patients with Cushing??s disease. Blood Coagulation and Fibrinolysis, 1992, 3, 789-794.	0.5	89
46	Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocrine Reviews, 2017, 38, 189-219.	8.9	88
47	Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2012, 59, 840-846.	1.3	87
48	MEDICAL THERAPY FOR CUSHING'S DISEASE. Endocrinology and Metabolism Clinics of North America, 1999, 28, 211-222.	1.2	83
49	Glucocorticoid-dependent hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 409-413.	1.2	82
50	Course of Depression in Cushing's Syndrome: Response to Treatment and Comparison with Graves' Disease. Hormone Research, 1993, 39, 202-206.	1.8	82
51	Persistent Psychological Distress in Patients Treated for Endocrine Disease. Psychotherapy and Psychosomatics, 2004, 73, 78-83.	4.0	82
52	Adrenocortical Carcinoma: Experience in 45 Patients. Oncology, 1997, 54, 490-496.	0.9	76
53	The Diagnosis of Cushing's Syndrome. Archives of Internal Medicine, 2000, 160, 3045.	4.3	76
54	Changes in Adenosine 5′-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4969-4973.	1.8	76

#	Article	IF	CITATIONS
55	Distinctive modulation of inflammatory and metabolic parameters in relation to zinc nutritional status in adult overweight/obese subjects. Journal of Nutritional Biochemistry, 2010, 21, 432-437.	1.9	73
56	Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. International Journal of Molecular Sciences, 2022, 23, 4110.	1.8	73
57	<i>IN VIVO</i> AND <i>IN VITRO</i> STUDIES ON THE EFFECT OF METOCLOPRAMIDE ON ALDOSTERONE SECRETION. Clinical Endocrinology, 1980, 13, 45-50.	1.2	71
58	Increased Factor VIII Associated Activities in Cushing's Syndrome: A Probable Hypercoagulable State. Thrombosis and Haemostasis, 1982, 47, 116-117.	1.8	71
59	Use of the Desmopressin Test in the Differential Diagnosis of Pseudo-Cushing State from Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1115-1122.	1.8	70
60	Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. Journal of Endocrinological Investigation, 2012, 35, 434-448.	1.8	69
61	Further Studies on the Hypercoagulable State of Patients with Cushing's Syndrome. Thrombosis and Haemostasis, 1985, 54, 518-520.	1.8	68
62	Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. European Journal of Endocrinology, 2006, 155, 435-441.	1.9	67
63	Sexual Symptoms in Endocrine Diseases: Psychosomatic Perspectives. Psychotherapy and Psychosomatics, 2007, 76, 134-140.	4.0	67
64	Bone health and aldosterone excess. Osteoporosis International, 2013, 24, 2801-2807.	1.3	65
65	Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5834-5840.	1.8	64
66	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	1.6	64
67	An analysis of different therapeutic options in patients with <scp>C</scp> ushing's syndrome due to bilateral macronodular adrenal hyperplasia: a singleâ€centre experience. Clinical Endocrinology, 2015, 82, 808-815.	1.2	62
68	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine, 2017, 55, 959-968.	1.1	62
69	Personality characteristics and quality of life in patients treated for Cushing's syndrome. Clinical Endocrinology, 2006, 64, 314-318.	1.2	60
70	Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine, 2014, 46, 370-386.	1.1	60
71	Investigations on the Morphology and Function of Adrenocortical Tissue Regenerated from Gland Capsular Fragments Autotransplanted in the Musculus Gracilis of the Rat. Endocrinology, 1990, 126, 3251-3262.	1.4	57
72	Age-Related Changes in Glucocorticoid Fast Feedback Inhibition of Adrenocorticotropin in Man1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1380-1383.	1.8	57

#	Article	IF	CITATIONS
73	P450c17 Deficiency: Clinical and Molecular Characterization of Six Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1000-1007.	1.8	57
74	Systematic review of surgical treatment of subclinical Cushing's syndrome. British Journal of Surgery, 2015, 102, 318-330.	0.1	57
75	Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3856-3861.	1.8	56
76	Managing Cushing's disease: the state of the art. Endocrine, 2014, 47, 9-20.	1.1	54
77	A role for life events in the pathogenesis of Cushing's disease. Clinical Endocrinology, 1993, 38, 261-264.	1.2	53
78	Self image and quality of life in acromegaly. Pituitary, 2002, 5, 17-19.	1.6	52
79	The ENDOTRIAL Study: A Spontaneous, Open-Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil, Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction. Journal of Sexual Medicine, 2009, 6, 2547-2560.	0.3	52
80	Coagulopathy in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 55-59.	1.2	52
81	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. Pituitary, 2016, 19, 488-495.	1.6	52
82	A Clinical Index for Rating Severity in Cushing's Syndrome. Psychotherapy and Psychosomatics, 2000, 69, 216-220.	4.0	51
83	Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. Scientific Reports, 2017, 7, 5474.	1.6	51
84	Coenzyme Q10 and male infertility. Journal of Endocrinological Investigation, 2009, 32, 626-632.	1.8	50
85	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. Journal of Neuro-Oncology, 2015, 122, 189-196.	1.4	50
86	Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2801-2804.	1.8	49
87	Clinical and molecular study in congenital muscular dystrophy with partial laminin ?2 (LAMA2) deficiency. Human Mutation, 2003, 21, 103-111.	1.1	49
88	Left ventricular structural characteristics in Cushing's syndrome. Journal of Human Hypertension, 1994, 8, 509-13.	1.0	49
89	Psychosocial impairment in patients treated for pituitary disease: a controlled study. Clinical Endocrinology, 2007, 67, 719-726.	1.2	48
90	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocrine Disorders, 2010, 10, 10.	0.9	48

MARCO BOSCARO

#	Article	IF	CITATIONS
91	Testosterone and cardiovascular risk. Internal and Emergency Medicine, 2013, 8, 65-69.	1.0	48
92	Cushing's Syndrome: Screening and Diagnosis. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 209-215.	1.0	48
93	Correlates of perceived health related quality of life in obese, overweight and normal weight older adults: an observational study. BMC Public Health, 2014, 14, 35.	1.2	47
94	The production of peroxynitrite by human spermatozoa may affect sperm motility through the formation of protein nitrotyrosine. Fertility and Sterility, 2006, 85, 947-953.	0.5	46
95	Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. European Journal of Endocrinology, 2012, 166, 35-42.	1.9	46
96	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary, 2015, 18, 604-612.	1.6	46
97	Life events in the pathogenesis of hyperprolactinemia. European Journal of Endocrinology, 2004, 151, 61-65.	1.9	45
98	Analysis of the 11β-Hydroxysteroid Dehydrogenase Type 2 Gene (HSD11B2) in Human Essential Hypertension. American Journal of Hypertension, 2005, 18, 1091-1098.	1.0	45
99	Effect of natural early menopause on bone mineral density. Maturitas, 2008, 59, 323-328.	1.0	45
100	Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?. Pituitary, 2015, 18, 487-493.	1.6	45
101	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. Clinical Science, 1981, 61, 289s-293s.	0.0	44
102	Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. Journal of Endocrinological Investigation, 1992, 15, 437-441.	1.8	44
103	Adipose Tissue as an Endocrine Organ? A Review of Recent Data Related to Cardiovascular Complications of Endocrine Dysfunctions. Clinical and Experimental Hypertension, 2004, 26, 387-398.	0.5	44
104	Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporosis International, 2014, 25, 913-921.	1.3	44
105	Metyrapone treatment in Cushing's syndrome: a real-life study. Endocrine, 2018, 62, 701-711.	1.1	44
106	Age-Related Changes in Glucocorticoid Fast Feedback Inhibition of Adrenocorticotropin in Man. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1380-1383.	1.8	44
107	Effect of surgical treatment on hypertension in Cushing's syndrome. American Journal of Hypertension, 1996, 9, 77-80.	1.0	43
108	Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2801-2804.	1.8	43

#	Article	IF	CITATIONS
109	Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. Pituitary, 2014, 17, 320-326.	1.6	42
110	Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. Journal of Internal Medicine, 1993, 234, 595-598.	2.7	41
111	Estrogen and thyroid cancer is a stem affair: A preliminary study. Biomedicine and Pharmacotherapy, 2017, 85, 399-411.	2.5	41
112	RESPONSE OF PITUITARYâ€ADRENAL AXIS TO CORTICOTROPHIN RELEASING HORMONE IN PATIENTS WITH CUSHING'S DISEASE BEFORE AND AFTER KETOCONAZOLE TREATMENT. Clinical Endocrinology, 1987, 27, 461-467.	1.2	40
113	Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary, 2000, 3, 55-59.	1.6	40
114	Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers. Current Genomics, 2011, 12, 618-625.	0.7	40
115	MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 AND ADRENAL LESIONS. Journal of Urology, 2001, 166, 24-27.	0.2	39
116	Visceral adipose tissue: emerging role of gluco―and mineralocorticoid hormones in the setting of cardiometabolic alterations. Annals of the New York Academy of Sciences, 2012, 1264, 87-102.	1.8	39
117	EFFECT OF BROMOCRIPTINE IN PITUITARYâ€DEPENDENT CUSHING'S SYNDROME. Clinical Endocrinology, 1983, 19, 485-491.	1.2	38
118	Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. European Journal of Endocrinology, 2003, 148, 73-80.	1.9	38
119	Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends in Endocrinology and Metabolism, 2008, 19, 104-108.	3.1	38
120	Free thiols in human spermatozoa: are Na+/K+-ATPase, Ca2+-ATPase activities involved in sperm motility through peroxynitrite formation?. Reproductive BioMedicine Online, 2009, 18, 132-140.	1.1	38
121	Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. European Journal of Endocrinology, 2009, 160, 891-898.	1.9	38
122	Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology, 2003, 59, 328-338.	1.2	37
123	Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clinical Endocrinology, 2011, 75, 666-672.	1.2	37
124	Role of bilateral adrenalectomy in Cushing's disease. World Journal of Surgery, 1994, 18, 462-466.	0.8	36
125	Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. International Journal of Cancer, 2004, 110, 914-920.	2.3	36
126	Metabolic syndrome in primary aldosteronism and essential hypertension: Relationship to adiponectin gene variants. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 93-100.	1.1	36

#	Article	IF	CITATIONS
127	Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. European Journal of Endocrinology, 2016, 175, 101-106.	1.9	36
128	Recovery of Bone Mineral Density after Surgical Cure, but not by Ketoconazole Treatment, in Cushing's Syndrome. Osteoporosis International, 2001, 12, 956-960.	1.3	35
129	Transcriptionally Targeted Retroviral Vector for Combined Suicide and Immunomodulating Gene Therapy of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5304-5311.	1.8	35
130	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. Endocrine, 2016, 52, 322-332.	1.1	35
131	Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. Cancer Gene Therapy, 2015, 22, 9-16.	2.2	34
132	Pharmacologic Management of Cushing Syndrome. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 87-94.	1.8	33
133	Oleoylethanolamide Protects Human Sperm Cells from Oxidation Stress: Studies on Cases of Idiopathic Infertility1. Biology of Reproduction, 2006, 74, 659-665.	1.2	33
134	OBESITY AND BODY MASS INDEX (BMI) IN RELATION TO LIFE-STYLE AND PSYCHO-SOCIAL ASPECTS. Archives of Gerontology and Geriatrics, 2009, 49, 195-206.	1.4	33
135	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence― Endocrine, 2019, 64, 657-672.	1.1	33
136	24-Hour Blood Pressure Profile in Addison's Disease. American Journal of Hypertension, 1994, 7, 1105-1109.	1.0	32
137	Slow-Release Lanreotide Treatment in Acromegaly: Effects on Quality of Life. Psychotherapy and Psychosomatics, 1999, 68, 165-167.	4.0	32
138	Vascular Endothelial Growth Factor and Microvessel Density in Periodontitis Patients With and Without Diabetes. Journal of Periodontology, 2009, 80, 1783-1789.	1.7	32
139	Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus. Journal of Periodontal Research, 2011, 46, 164-169.	1.4	32
140	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. Endocrine, 2018, 59, 510-519.	1.1	32
141	STRESSFUL LIFE EVENTS IN THE PATHOGENESIS OF CUSHING'S SYNDROME. Clinical Endocrinology, 1988, 29, 617-623.	1.2	30
142	Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Pressure, 2005, 14, 227-232.	0.7	30
143	First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. Journal of Endocrinological Investigation, 2017, 40, 753-760.	1.8	30
144	Effect of serotonin on plasma aldosterone in man. Journal of Endocrinological Investigation, 1982, 5, 97-99.	1.8	29

#	Article	IF	CITATIONS
145	Evidence for Ultra-Short Loop Autoregulation of Adrenocorticotropin Secretion in Man. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 255-257.	1.8	28
146	Paclitaxel Is an Effective Antiproliferative Agent on the Human NCI-H295 Adrenocortical Carcinoma Cell Line. Chemotherapy, 1998, 44, 129-134.	0.8	28
147	Adrenal incidentaloma: Surgical update. Journal of Endocrinological Investigation, 2007, 30, 200-204.	1.8	28
148	Sexual Dysfunctions in Men Affected by Autoimmune Addison's Disease Before and After Short-Term Gluco- and Mineralocorticoid Replacement Therapy. Journal of Sexual Medicine, 2013, 10, 2036-2043.	0.3	28
149	25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese. Osteoporosis International, 2016, 27, 2593-2602.	1.3	28
150	Selective Venous Sampling in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. Neuroendocrinology, 1992, 55, 264-268.	1.2	27
151	Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency Journal of Clinical Endocrinology and Metabolism, 1994, 79, 452-455.	1.8	27
152	Coexistence of Aldosteronoma and Contralateral Nonfunctioning Adrenal Adenoma in Primary Aldosteronism. American Journal of Hypertension, 1997, 10, 476-478.	1.0	27
153	A New Germline Point Mutation in Ret Exon 8 (Cys ⁵¹⁵ Ser) in a Family with Medullary Thyroid Carcinoma. Thyroid, 2008, 18, 775-782.	2.4	27
154	Have androgen receptor gene CAG and GGC repeat polymorphisms an effect on sperm motility in infertile men?. Andrologia, 2014, 46, 564-569.	1.0	27
155	Anaplastic Thyroid Carcinoma. Frontiers in Endocrinology, 2012, 3, 84.	1.5	26
156	A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome. Hormone and Metabolic Research, 2016, 48, 290-298.	0.7	26
157	Plasma Renin Activity and Urinary Aldosterone in Cushing's Syndrome. Hormone and Metabolic Research, 1978, 10, 65-71.	0.7	25
158	Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism. Clinical Endocrinology, 2011, 74, 278-279.	1.2	25
159	Primary aldosteronism and essential hypertension: Assessment of cardiovascular risk at diagnosis and after treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 476-482.	1.1	25
160	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary, 2015, 18, 359-365.	1.6	25
161	An in vitro stimulatory effect of indoleamines on aldosterone biosynthesis in the rat. The Journal of Steroid Biochemistry, 1982, 17, 351-355.	1.3	24
162	Endocrine Aspects of Cancer Gene Therapy. Endocrine Reviews, 2004, 25, 1-44.	8.9	24

#	Article	IF	CITATIONS
163	Chemical-physical properties of lipoproteins in anorexia nervosa. European Journal of Clinical Investigation, 2004, 34, 747-751.	1.7	24
164	Protective effect of leg fat against cardiovascular risk factors in obese premenopausal women. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 39-44.	1.1	24
165	Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2542-2546.	1.3	24
166	Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocrine Connections, 2018, 7, 965-974.	0.8	24
167	Diagnosis and management of adrenal incidentalomas. Journal of Urology, 2000, 163, 398-407.	0.2	24
168	New perspectives for gene therapy in endocrinology. European Journal of Endocrinology, 2000, 143, 447-466.	1.9	23
169	Synergistic antitumour activity of <scp>RAF</scp> 265 and <scp>ZSTK</scp> 474 on human <scp>TT</scp> medullary thyroid cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 2244-2252.	1.6	23
170	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	1.5	23
171	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget, 2015, 6, 32104-32114.	0.8	23
172	Adipose cell–adrenal interactions: current knowledge and future perspectives. Trends in Endocrinology and Metabolism, 2008, 19, 100-103.	3.1	22
173	Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. European Journal of Endocrinology, 2009, 160, 639-646.	1.9	22
174	Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists. Current Vascular Pharmacology, 2012, 10, 238-246.	0.8	22
175	The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Investigational New Drugs, 2014, 32, 626-635.	1.2	22
176	Clinical use of pasireotide for Cushing's disease in adults. Therapeutics and Clinical Risk Management, 2015, 11, 425.	0.9	22
177	Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors. Endocrine, 2018, 59, 280-287.	1.1	22
178	Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine, 2018, 59, 319-329.	1.1	22
179	Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3938-e3949.	1.8	22
180	Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thrombosis and Haemostasis, 1982, 47, 116-7.	1.8	22

#	Article	IF	CITATIONS
181	Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies. Journal of Endocrinological Investigation, 1982, 5, 173-177.	1.8	21
182	Idiopathic Infertility: Effect of Palmitoylethanolamide (a Homologue of Anandamide) on Hyperactivated Sperm Cell Motility and Ca2+ Influx. Journal of Andrology, 2005, 26, 429-436.	2.0	21
183	Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis, 1985, 54, 518-20.	1.8	21
184	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. Hormone and Metabolic Research, 1981, 13, 464-467.	0.7	20
185	Regression of cardiac abnormalities after replacement therapy in Addison's disease. European Journal of Endocrinology, 1999, 140, 425-428.	1.9	20
186	Idiopathic infertility: susceptibility of spermatozoa to in-vitro capacitation, in the presence and the absence of palmitylethanolamide (a homologue of anandamide), is strongly correlated with membrane polarity studied by Laurdan fluorescence. Molecular Human Reproduction, 2003, 9, 381-388.	1.3	20
187	Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. Pituitary, 2015, 18, 60-67.	1.6	20
188	Plasma renin activity and urinary aldosterone in acromegaly. Journal of Endocrinological Investigation, 1979, 2, 13-18.	1.8	19
189	In SituAnalysis of Human Menin in Normal and Neoplastic Pancreatic Tissues: Evidence for Differential Expression in Exocrine and Endocrine Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3893-3901.	1.8	19
190	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTHâ€dependent Cushing's syndrome. Clinical Endocrinology, 2017, 87, 500-507.	1.2	19
191	Crude extract of <i>Origanum vulgare</i> L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines. Natural Product Research, 2019, 33, 1646-1649.	1.0	19
192	Adrenal morpho-functional alterations in patients with acromegaly. Journal of Endocrinological Investigation, 2008, 31, 602-606.	1.8	18
193	Pasireotide for the treatment of Cushing's disease. Expert Opinion on Investigational Drugs, 2010, 19, 889-898.	1.9	18
194	Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment. Current Vascular Pharmacology, 2009, 7, 244-249.	0.8	18
195	Corticotropin releasing hormone stimulation test: diagnostic aspects in Cushing's syndrome. Journal of Endocrinological Investigation, 1987, 10, 297-302.	1.8	17
196	Steroids and hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 35-44.	1.2	17
197	Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas. European Journal of Endocrinology, 2001, 145, 223-224.	1.9	17
198	Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 452-455.	1.8	17

#	Article	IF	CITATIONS
199	Psychological Distress and Quality of Life in Endocrine Disease. Psychotherapy and Psychosomatics, 1990, 54, 140-144.	4.0	16
200	Low-dose ketoconazole treatment in hirsute women. Journal of Endocrinological Investigation, 1990, 13, 35-40.	1.8	16
201	A Pilot Study of Combined Suicide/Cytokine Gene Therapy in Two Patients with End-Stage Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2831-2834.	1.8	16
202	Role of raloxifene on platelet metabolism and plasma lipids. European Journal of Clinical Investigation, 2008, 38, 117-125.	1.7	16
203	Diagnosis and management of primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 332-338.	1.2	16
204	New Insight into the Hypercoagulability of Cushing's Syndrome. Neuroendocrinology, 2011, 93, 121-125.	1.2	16
205	Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. Journal of Endocrinological Investigation, 2016, 39, 1015-1021.	1.8	16
206	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. Endocrine, 2018, 61, 118-124.	1.1	16
207	Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 345-354.	1.0	16
208	Defects of steroidogenesis. Journal of Endocrinological Investigation, 2010, 33, 756-766.	1.8	15
209	Evaluation of angiotensin <scp>II</scp> typeâ€l receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. Journal of Clinical Hypertension, 2018, 20, 1313-1318.	1.0	15
210	A multidisciplinary approach to the management of adrenal incidentaloma. Expert Review of Endocrinology and Metabolism, 2021, 16, 201-212.	1.2	15
211	Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. Journal of Endocrinological Investigation, 2022, 45, 629-637.	1.8	15
212	Increased factor VIII/vWf levels in patients with reduced platelet number. Blut, 1987, 54, 281-288.	1.2	14
213	Corticotropin-Releasing Effect of Hexarelin, a Peptidyl GH Secretagogue, in Normal Subjects Pretreated with Metyrapone or RU-486, a Glucocorticoid Receptor Antagonist, and in Patients with Addison's Disease. Neuroendocrinology, 1999, 70, 200-206.	1.2	14
214	Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World Journal of Biological Psychiatry, 2010, 11, 991-996.	1.3	14
215	Blood Pressure, Thyroid-Stimulating Hormone, and Thyroid Disease Prevalence in Primary Aldosteronism and Essential Hypertension. American Journal of Hypertension, 2011, 24, 1274-1279.	1.0	14
216	Investigation of N-cadherin/β-catenin expression in adrenocortical tumors. Tumor Biology, 2016, 37, 13545-13555.	0.8	14

#	Article	IF	CITATIONS
217	Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. Journal of Endocrinological Investigation, 2021, 44, 2749-2763.	1.8	14
218	Type I and type II disease in congenital factor XIII deficiency. Blut, 1986, 53, 411-413.	1.2	13
219	Effect of Naloxone on the Adrenal Cortex in Primary Aldosteronism. American Journal of Hypertension, 1988, 1, 280-282.	1.0	13
220	Effects of prolonged sodium restriction on the morphology and function of rat adrenocortical autotransplants. Cell and Tissue Research, 1991, 265, 35-41.	1.5	13
221	Effect of Octreotide on 24-h Blood Pressure Profile in Acromegaly. American Journal of Hypertension, 1998, 11, 591-596.	1.0	13
222	Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. Clinical Endocrinology, 2005, 62, 533-538.	1.2	13
223	Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample. Hormones, 2015, 14, 392-8.	0.9	13
224	The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. Investigational New Drugs, 2016, 34, 531-540.	1.2	13
225	Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. Klinische Wochenschrift, 1987, 65, 437-444.	0.6	12
226	Inhibition of Pituitary β-Endorphin by ACTH and Glucocorticoids. Neuroendocrinology, 1990, 51, 561-564.	1.2	12
227	New Aspects of Mineralocorticoid Hypertension. Hormone Research, 1990, 34, 175-180.	1.8	12
228	Disseminated nocardiosis in a patient with Cushing's syndrome. Journal of Endocrinological Investigation, 1994, 17, 443-445.	1.8	12
229	Gene therapy for thyroid cancer. Expert Opinion on Biological Therapy, 2004, 4, 1225-1239.	1.4	12
230	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. Endocrine, 2015, 50, 154-161.	1.1	12
231	GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp. Carcinogenesis, 1995, 16, 1643-1645.	1.3	11
232	Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism: Clinical and Experimental, 2008, 57, 593-597.	1.5	11
233	Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation. Journal of Endocrinological Investigation, 2012, 35, 590-4.	1.8	11
234	Intrapituitary cytokines in Cushing's disease: do they play a role?. Pituitary, 2011, 14, 236-241.	1.6	10

#	Article	IF	CITATIONS
235	Increase in vascular permeability produced in rat airways by PAF: potentiation by adrenalectomy. British Journal of Pharmacology, 1992, 105, 388-392.	2.7	9
236	Percutaneous Therapy of Varicocele: Effects on Semen Parameters in Young Adults. Urologia Internationalis, 2004, 72, 150-153.	0.6	9
237	Vitamin D levels and bone mineral density: are LH levels involved in the pathogenesis of bone impairment in hypogonadal men?. Journal of Endocrinological Investigation, 2014, 37, 1225-1231.	1.8	9
238	Association of primary aldosteronism with chronic thyroiditis. Endocrine, 2017, 55, 303-306.	1.1	9
239	Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proofâ€ofâ€concept study. Clinical Endocrinology, 2018, 88, 201-208.	1.2	9
240	Circadian Secretion of Acth, Cortisol, and Mineralocorticoids in Cushing's Syndrome. Clinical and Experimental Hypertension, 1982, 4, 1779-1794.	0.3	8
241	Adrenal Scintigraphy in the Morphological and Functional Evaluation of Cushing's Syndrome. Cardiology, 1985, 72, 76-83.	0.6	8
242	Evidence for ectopic ACTH production years after bilateral adrenalectomy for Cushing's syndrome: in vivo and in vitro studies. Journal of Endocrinological Investigation, 1985, 8, 417-421.	1.8	8
243	Effect of α-Human Atrial Natriuretic Peptide in Low Renin Essential Hypertension and Primary Aldosteronism. Clinical and Experimental Hypertension, 1987, 9, 1505-1513.	0.3	8
244	Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Rheumatology International, 1995, 14, 207-211.	1.5	8
245	Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. Cancer Gene Therapy, 2005, 12, 381-388.	2.2	8
246	Aldosterone, Calcium, and Hypertension. American Journal of Nephrology, 1986, 6, 33-39.	1.4	7
247	Atrial natriuretic peptide in Cushing's disease. Journal of Endocrinological Investigation, 1990, 13, 133-137.	1.8	7
248	Patterns of ACTH Response to oCRH in Cushing's Disease: Correlation with Histological/Immunocytochemical Findings. Neuroendocrinology, 1994, 60, 237-242.	1.2	7
249	New treatment guidelines on Cushing's disease. F1000 Medicine Reports, 2009, 1, .	2.9	7
250	Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?. Journal of Endocrinological Investigation, 2014, 37, 957-965.	1.8	7
251	Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients. Journal of Endocrinological Investigation, 2015, 38, 389-397.	1.8	7
252	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Microvascular Research, 2020, 128, 103940.	1.1	7

#	Article	IF	CITATIONS
253	Growth hormone deficiency in the transition period: body composition and gonad function. Journal of Endocrinological Investigation, 2011, 34, 709-15.	1.8	7
254	Adrenocortical carcinoma: epidemiology and natural history. Minerva Endocrinologica, 1995, 20, 89-94.	1.7	7
255	Lipoproteins Obtained from Anorexia Nervosa Patients Induce Higher Oxidative Stress in U373MG Astrocytes Through Nitric Oxide Production. NeuroMolecular Medicine, 2008, 10, 17-23.	1.8	6
256	Cortical adrenal mitochondrial morphology changes in functional state: new insights. Cell and Tissue Research, 2013, 351, 409-417.	1.5	6
257	Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors. Cancer Investigation, 2015, 33, 526-531.	0.6	6
258	Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. Hormone and Metabolic Research, 2016, 48, 514-519.	0.7	6
259	Body Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study. Hormone and Metabolic Research, 2017, 49, 660-666.	0.7	6
260	Effect of short and long-term administration of lisuride in Cushing's disease. Journal of Endocrinological Investigation, 1985, 8, 13-17.	1.8	5
261	Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women. Current Pharmaceutical Design, 2005, 11, 4187-4206.	0.9	5
262	Human leucocytes in asthenozoospermic patients: endothelial nitric oxide synthase expression. Andrologia, 2014, 46, 1176-1182.	1.0	5
263	EFFECTS OF NALOXONE ON THE PITUITARYâ€ADRENAL AXIS IN PATIENTS WITH DEXAMETHASONEâ€5UPPRESSI HYPERALDOSTERONISM. Clinical Endocrinology, 1987, 26, 163-168.	BLE 1.2	4
264	Advances in medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2007, 2, 735-743.	1.2	4
265	The role of psychological well-being in obese and overweight older adults. International Psychogeriatrics, 2016, 28, 171-172.	0.6	4
266	Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. Pituitary, 2018, 21, 50-55.	1.6	4
267	Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. Endocrine Connections, 2021, 10, 1189-1199.	0.8	4
268	DIAGNOSIS AND MANAGEMENT OF ADRENAL INCIDENTALOMAS. Journal of Urology, 2000, , 398.	0.2	4
269	Effect of a Synthetic Substituted α1-18 ACTH on Mineralocorticoid Secretion. Hormone and Metabolic Research, 1980, 12, 464-470.	0.7	3
270	Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. The Journal of Steroid Biochemistry, 1983, 19, 531-536.	1.3	3

#	Article	IF	CITATIONS
271	Serum levels of calcitonin in Cushing's syndrome. Journal of Endocrinological Investigation, 1986, 9, 239-241.	1.8	3
272	Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. Journal of Endocrinological Investigation, 1988, 11, 261-265.	1.8	3
273	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism. Journal of Hypertension, 2006, 24, 1899-1900.	0.3	3
274	Evaluation and implications of salt intake and excretion. Journal of Clinical Hypertension, 2019, 21, 950-952.	1.0	3
275	Alpha-1 adrenergic blockade: a possible mechanism of action of dopaminergic drugs on ACTH secretion. Journal of Endocrinological Investigation, 1985, 8, 523-526.	1.8	2
276	Factor XII activation after DDAVP. Thrombosis Research, 1990, 58, 531-532.	0.8	2
277	Clinical Symposium. Journal of Endocrinological Investigation, 1992, 15, 223-244.	1.8	2
278	Hypogonadism and Reduced Bone Mineral Density in Heterozygous H63D Mutation in the HFE Gene: An Unusual Presentation of Hereditary Hemochromatosis. Journal of Andrology, 2006, 28, 21-26.	2.0	2
279	The Prevalence of HTLV-III and HTLV-I Antibodies in Serum of Hemophiliacs. Thrombosis and Haemostasis, 1985, 54, 897-897.	1.8	2
280	Is this a seizure?. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 89.	1.0	2
281	Potential therapeutic effects of ritanserin in Cushing's disease. JAMA - Journal of the American Medical Association, 1992, 267, 1073.	3.8	2
282	Pituitary microadenomas: Surgical results and morphological findings. Acta Neurochirurgica, 1983, 69, 231-242.	0.9	1
283	Pro-gamma-MSH levels in various disorders of pituitary-adrenal axis. Journal of Endocrinological Investigation, 1990, 13, 29-33.	1.8	1
284	Gene therapy for thyroid cancer. Expert Review of Endocrinology and Metabolism, 2006, 1, 367-378.	1.2	1
285	Pituitary-directed medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2009, 4, 263-272.	1.2	1
286	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 963.	1.9	1
287	Hypertension in Cushing's Syndrome. Updates in Hypertension and Cardiovascular Protection, 2020, , 127-139.	0.1	1
288	Unilateral primary aldosteronism considerations about the diagnostic criteria, adrenalectomy, and short and long time biochemical and clinical evaluation. Journal of Clinical Hypertension, 2022, 24, 116-118.	1.0	1

#	Article	IF	CITATIONS
289	Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism. Journal of Endocrinological Investigation, 2013, 36, 50-4.	1.8	1
290	217. Effect of metoclopramide on plasma aldosterone: in vivo and in vitro studies. The Journal of Steroid Biochemistry, 1978, 9, 858.	1.3	0
291	Diagnosi della sindrome di Cushing. L Endocrinologo, 2005, 6, 137-142.	0.0	0
292	lpo- e iperpotassiemie nella pratica clinica: percorsi diagnostici e terapeutici. L Endocrinologo, 2009, 10, 2-15.	0.0	0
293	Complicanze cardiometaboliche e renali nell'iperaldosteronismo primario. L Endocrinologo, 2011, 12, 111-116.	0.0	0
294	Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment. Journal of Endocrinological Investigation, 2021, 44, 2009-2010.	1.8	0
295	EFFECT OF METERGOLINE ON THE ALDOSTERONE-STIMULATING PROPERTIES OF METOCLOPRAMIDE. , 1983, , 531-536.		0